scholarly journals Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component

2017 ◽  
Author(s):  
Sergio Caravita ◽  
Andrea Faini ◽  
Antoine Bondue ◽  
Robert Naeije ◽  
Gianfranco Parati ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Left Heart ◽  
Clinical Phenotypes ◽  
Left Heart Disease

scholarly journals Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199164 ◽  
Author(s):  
Sergio Caravita ◽  
Andrea Faini ◽  
Sandy Carolino D’Araujo ◽  
Céline Dewachter ◽  
Laura Chomette ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Left Heart ◽  
Clinical Phenotypes ◽  
Left Heart Disease

scholarly journals Pulmonary Hypertension Due to Left Heart Disease—Combine or Not Combined? DPG In or Out? A Practical Approach to the Patient With Suspected Left Heart Disease

2019 ◽  
Vol 18 (3) ◽  
pp. 87-91
Author(s):  
Thenappan Thenappan
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Left Heart ◽  
Common Cause ◽  
Pulmonary Vasodilators ◽  
Left Heart Disease ◽  
Pulmonary Arterial

Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common cause of PH in clinical practice. The definition and classification of PH-LHD has evolved in the last 5 years from the 5th World Symposium on PH (WSPH) in 2013 to the most recent 6th WSPH in 2018. Differentiation of PH-LHD, especially PH due to heart failure with preserved ejection from pulmonary arterial hypertension and chronic thromboembolic PH, can be very challenging. Finally, there is unclarity on the role of pulmonary vasodilators in the treatment of PH-LHD. The 6th WSPH consensus proceedings addresses all these topics in a detailed manner. In this article, we review the changes proposed by the 6th WSPH consensus proceedings in the definition, classification, diagnostic evaluation, and treatment of PH-LHD.

Characterization of a Pulmonary Hypertension Model Caused by Left Heart Disease in Mouse

2020 ◽  
Author(s):  
L. K. Pallos ◽  
J. M. Dietrich ◽  
A. Simon ◽  
E. Carls ◽  
M. Matthey ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Left Heart ◽  
Left Heart Disease

Roundtable: Pulmonary Hypertension Due to Left Heart Disease

2015 ◽  
Vol 14 (2) ◽  
pp. 105-110
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Guest Editor ◽  
Mayo Clinic ◽  
Diagnosis And Treatment ◽  
Left Heart ◽  
Health Network ◽  
University Of Utah ◽  
School Of Medicine ◽  
Left Heart Disease

Guest editor Teresa De Marco, MD, along with Brian Shapiro, MD, Mayo Clinic, Jacksonville, FL, convened a panel of experts to discuss the challenges in diagnosis and treatment and the emerging science regarding pulmonary hypertension due to left heart disease. Contributing to the engaging discussion were James Fang, MD, University of Utah School of Medicine; Barry Borlaug, MD, Mayo Clinic, Rochester, MN; and Srinivas Murali, MD, Allegheny Health Network, Pittsburgh, PA.

Pulmonary Hypertension secondary to Left Heart Disease

2018 ◽  
Vol 16 (6) ◽  
pp. 555-560 ◽  
Author(s):  
Ghazal Kabbach ◽  
Debabrata Mukherjee
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Left Heart ◽  
Left Heart Disease

scholarly journals Under pressure: pulmonary hypertension associated with left heart disease

2015 ◽  
Vol 24 (138) ◽  
pp. 665-673 ◽  
Author(s):  
Harrison W. Farber ◽  
Simon Gibbs
Keyword(s):  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Survival Rates ◽  
Left Ventricular ◽  
Left Heart ◽  
Mean Pulmonary Arterial Pressure ◽  
Left Heart Disease ◽  
Right Heart Catheterisation ◽  
Pulmonary Capillary ◽  
Pulmonary Arterial

Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood. PH-LHD is diagnosed by right heart catheterisation with a mean pulmonary arterial pressure ≥25 mmHg and a pulmonary capillary wedge pressure >15 mmHg. The primary causes of PH-LHD are left ventricular dysfunction of systolic and diastolic origin, and valvular disease. Prognosis is poor and survival rates are low. Limited progress has been made towards specific therapies for PH-LHD, and management focuses on addressing the underlying cause of the disease with supportive therapies, surgery and pharmacological treatments. Clinical trials of therapies for pulmonary arterial hypertension in patients with PH-LHD have thus far been limited and have provided disappointing or conflicting results. Robust, long-term clinical studies in appropriate target populations have the potential to improve the outlook for patients with PH-LHD. Herein, we discuss the knowledge gaps in our understanding of PH-LHD, and describe the current unmet needs and challenges that are faced by clinicians when identifying and managing patients with this disease.

Sign in / Sign up

Export Citation Format

Share Document